BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 01/04/23

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer PR Newswire NEW YORK , Jan. 4, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for...

BrainStorm Cell Therapeutics ( NASDAQ: BCLI ) said the U.S. Food and Drug Administration (FDA) granted a Type A meeting to discuss a letter issued by the agency which had declined to accept the company's application seeking approval of NurOwn to treat amyotrophic l...

BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn® PR Newswire NEW YORK , Dec. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegene...

BrainStorm Announces Presentations at June 2022 Scientific Conferences PR Newswire Analyses accounting for ALSFRS-R floor effect in ALS yields new results to be presented at the ENCALS meeting in Edinburgh, Scotland Clinical, biomarker and preclinical data from N...

Most of us know someone affected by hearing loss, but we may not fully appreciate the hardships that lack of hearing can bring. Hearing loss can lead to isolation, frustration, and a debilitating ringing in the ears known as tinnitus. It is also closely correlated with dementia. Read More >...

Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2022 Earnings Conference Call May 16, 2022 8:00 A.M. ET Company Participants Tom Galassi - Investor Relations, LifeSci Advisors Chaim Lebovits - Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Stacy Lindborg - Executive Vice Pr...

BrainStorm Cell Therapeutics press release (NASDAQ:BCLI): Q1 GAAP EPS of -$0.15 misses by $0.02. "We remain firmly committed to addressing the urgent needs of ALS patients by working expeditiously towards our goal of enabling broad access to NurOwn®," said Chaim Lebovits, Chief Exec...

BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update PR Newswire BrainStorm continues to gain insights and perspectives from leading ALS experts as it seeks the optimal path forward to provide broad patient access ...

BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal PR Newswire Netta Blondheim-Shraga , PhD Appointed as VP R&D Antal Pearl-Lendner, Adv. App...

BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting PR Newswire NurOwn-derived exosomes showed more potent anti-inflammatory effects in vitro compared to naïve mesenchymal stem cell-derived exosomes ...